JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/refractory Indolent T/NK-cell Lymphomas
Status:
RECRUITING
Trial end date:
2028-11-15
Target enrollment:
Participant gender:
Summary
Indolent T/NK-cell lymphomas are a heterogeneous group of lymphoproliferative diseases originating from T/NK cells, characterized by slow growth and proliferation, but currently remain incurable. For indolent T/NK-cell lymphomas that are unresponsive to first-line treatment, there are few treatment options available and the prognosis is poor. This study is an open-label, prospective clinical trial aimed at evaluating the feasibility, efficacy, and safety of PI3K inhibitors in the treatment of relapsed/refractory indolent T/NK-cell lymphomas. Patients will be treated with Golidocitnib, with an expected overall response rate of 60% for JAK1 inhibitor Golidocitnib treatment.
Phase:
PHASE2
Details
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China
Collaborators:
Henan Cancer Hospital Second Xiangya Hospital of Central South University The First Affiliated Hospital of Air Force Medicial University The First Affiliated Hospital of Nanchang University The First Hospital of Jilin University Tianjin First Central Hospital Tongji Hospital